Hologic has been identified as one of five leading players advancing portable, AI-powered diagnostic platforms that bring hospital-grade MRI precision to bedside applications. The global point-of-care diagnostics market is forecast to reach $70.92 billion by 2032, and the introduction of the CMS ACCESS Model in July 2026—offering outcome-based reimbursement—provides a strong incentive for health systems to adopt software-defined imaging solutions. Hologic’s initiatives in this space focus on integrating its proprietary AI algorithms with compact imaging hardware, aiming to reduce facility overhead by up to 30 percent while maintaining diagnostic accuracy above 95 percent in conditions such as breast cancer and musculoskeletal injuries.

On January 15, Hologic rolled out Ultimate Defense, a nationwide U.S. campaign designed to combat rising underscreening rates for cervical cancer. The initiative promotes combined Pap and HPV testing, citing data that shows dual screening can increase early detection rates by 40 percent compared to Pap testing alone. Hologic plans to deploy educational materials to over 5,000 clinics this quarter and partner with patient advocacy groups to reach an estimated 1.2 million women who are overdue for screening.

Hologic confirmed it will issue its first-quarter fiscal 2026 financial results after market close on Thursday, January 29, 2026. In light of its pending acquisition by Blackstone and TPG, the company will not host a conference call or provide formal guidance for the period. Investors will receive a detailed earnings release outlining revenue comparisons to the prior year’s quarter and segment performance across diagnostics, surgical, and cytology products.